The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bodaghi, B.
Right arrow Articles by Michelson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bodaghi, B.
Right arrow Articles by Michelson, S.
The Journal of Immunology, 1999, 162: 957-964.
Copyright © 1999 by The American Association of Immunologists

Role of IFN-{gamma}-Induced Indoleamine 2,3 Dioxygenase and Inducible Nitric Oxide Synthase in the Replication of Human Cytomegalovirus in Retinal Pigment Epithelial Cells1

Bahram Bodaghi2,*, Olivier Goureau{dagger}, Donato Zipeto*, Lysiane Laurent*, Jean-Louis Virelizier* and Susan Michelson*

* Unité d’Immunologie Virale, Institut Pasteur, Paris, France; and {dagger} Institut National de la Santé et de la Recherche Médicale, U450, Developpement, Vieillissement et Pathologie de la Rétine, Paris, France


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
An in vitro model of human CMV infection of primary retinal pigment epithelial (RPE) cells was used to study the effects of cytokines on CMV replication in these cells, which are targets of CMV infection in vivo. IFN-{gamma} and IFN-ß were potent inhibitors of CMV replication in RPE cells, while TNF-{alpha}, IL-1ß, or TGF-ß2 did not affect viral replication. Inhibition by IFN-{gamma}, and to a lesser extent IFN-ß, was almost completely reversed by addition of L-tryptophan to the culture medium, strongly implicating the indoleamine 2,3 dioxygenase (IDO) pathway. Polyadenylated IDO mRNA accumulation was detected as early as 2 h after IFN stimulation. Furthermore, CMV blocked the production of nitric oxide by the inducible form of nitric oxide synthase. This inhibition depended on a functional viral genome. However, exogenous nitric oxide significantly inhibited viral protein expression in RPE cells. Thus, CMV infection blocks the inducible nitric oxide synthase pathway activated by IFN-{gamma} and IL-1ß, but cannot counteract the IFN-induced IDO pathway, which ultimately controls its replication in primary human RPE cells.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The intraocular environment maintains a special relationship with the immune system (1, 2). Ocular immune privilege exists not only in the anterior segment, but also in the posterior segment of the eye (3, 4). Under normal conditions, this phenomenon relies largely on TGF-ß2, which can potentially inhibit IFN-{gamma}-induced up-regulation of class II Ags on human retinal pigment epithelial (RPE)3 cells, thereby altering their characteristics as APCs (5). Fas ligand, which is constitutively expressed on the neurosensory retina and on RPE cells, also plays an important role (6). Human retinal pigment epithelium is a multifunctional and strategic component of the retina (7). It forms part of the blood retinal barrier, the other part being at the level of retinal blood vessels. The pigment epithelium allows continuous renewal of the outer segments of photoreceptors via specialized phagocytosis.

CMV retinitis, one of the most common opportunistic infections in HIV-infected patients (8, 9), manifests itself when the patient’s CD4+ lymphocyte counts are less than 100/mm3. The pathophysiology of this retinal disease remains poorly understood. The onset of CMV retinitis presumably results from alterations in the ocular immune privilege status and/or in the antiviral mechanisms effective until retinal infection occurs. All 10 layers of the retina are sites of necrotic lesions. However, CMV seems to replicate efficiently only in RPE and glial cells (10, 11). It has been shown that both primary cell types are fully permissive for CMV infection in vitro, even if the cycle seems to be protracted compared with that in routinely used targets for CMV replication such as diploid fibroblasts (12, 13).

Issues concerning the influence of cytokines on viral disease progression are still under debate. The occurrence of CMV disease in the late phase of immunosuppression may be related to perturbation of cytokine production and secretion, associated with the progressive loss of the CD3+CD8+ cell subset (14). During ocular inflammation, inflammatory mediators, such as IFN-{gamma} and TNF-{alpha}, are detected in the vitreous humor and the retina of HIV-infected patients presenting with CMV retinitis (15, 16).

The antiviral effects of IFNs have been principally attributed to 1) the phosphorylation of eukaryotic protein synthesis initiation factor eIF-2{alpha} by P1 kinase; 2) the activation of a latent endoribonuclease by the end products of 2',5'-oligoadenylate synthetase; and finally 3) expression of Mx proteins during infections with influenza and vesicular stomatitis viruses (17, 18). Previous studies have shown that IFN-{gamma} and IFN-ß inhibit CMV replication in vitro and in vivo (19, 20, 21, 22). However, the mechanisms of this inhibition are still unclear. In human and bovine retina, IFN-{gamma} can induce the expression of indoleamine 2,3 dioxygenase (IDO) (23, 24) and, in combination with IL-1ß, the inducible form of nitric oxide synthase (NOSII) (25). IDO is responsible for conversion of tryptophan and other indole derivatives to kynurenine (26), thus explaining the inhibitory effect of IFN on many intracellular organisms, such as Toxoplasma gondii and Chlamydia psittaci (27, 28). NOSII has been shown to have antiviral effects in different models (29, 30, 31, 32, 33, 34, 35). Much evidence has previously highlighted the role played by the inducible form of NOSII in ocular inflammatory and infectious disorders (36). This enzyme is responsible for the synthesis of nitric oxide (NO) from L-arginine. At least two major retinal components express NOSII. It has been shown that CMV-infected retinal glial cells from HIV-infected patients express NOSII (37). Human RPE cells are another major source of NOSII in vitro and possibly in vivo, even though enzyme expression is easily masked by the large amounts of pigment present in the cells (25, 26).

In the current study, we analyzed the influence on human CMV replication of different cytokines known to be present in the eye under normal conditions or during different inflammatory disorders and infectious diseases, and which have been reported to affect CMV replication in vivo or in vitro. It was possible to show that inhibition of CMV replication by IFN-{gamma}, and less markedly by IFN-ß, involves the IDO pathway. Furthermore, exogenously added nitric oxide (NO) showed a clear, antiviral effect in RPE cells, but CMV infection inhibited endogenous NO production by NOSII.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Human research

The tenets of the Declaration of Helsinki were followed, and approval was obtained from the Office of Human Subjects Research.

Cell cultures

Primary human RPE cell lines were established from donor eyes. Human eyes were obtained from the Bristol Eye Bank (a generous gift from Dr. M. Nash, Oxford, U.K.) after removal of corneas for transplantation. RPE cells were isolated by trypsinization, resuspended in HAM-F10 (Life Technologies, Cergy Pontoise, France) with 10% heat-inactivated FCS, and transferred to a 25-cm2 flask. RPE cells form monolayers like epithelial cells and at confluency are typically hexagonal. Homogeneity was confirmed by positive immunostaining with mAbs to cytokeratins (38). Cultures from three different primary cell lines were used at passages 3–11 for all experiments. All cells were routinely tested for mycoplasma and found to be negative.

Virus

Human CMV strain AD169 was used throughout. Stocks of CMV were generated in human foreskin fibroblasts, and titers were determined by plaque formation under 0.64% carboxymethyl cellulose, as previously described (39). Titration was performed for all stocks using both passive particle adsorption and centrifugal enhancement (40); centrifugation usually resulted in a 0.5–1 log enhancement of virus titers compared with passive adsorption. UV inactivation of CMV (6 x 105 joules) resulted in a reduction of the viral titer from 2 x 106 to less than 50 plaque-forming units/ml. Inactivated virus was tested for its capacity to induce IE proteins and found to be negative 24 h after virus adsorption. Heat-inactivated virus (56°C, 30 min) and UV-irradiated CMV were used at the same multiplicities of infection (MOI), based on preinactivation titers of the viral stock. For all experiments, virus was adsorbed to cells for 2 h at 37°C. Cells were then washed twice with PBS and refed complete medium. Infection times are indicated in Results. All virus stocks were negative for the presence of mycoplasma.

Chemicals

Human rIFN-{gamma} and rIL-1ß were purchased from Peprotech, TEBU (France). Human rTNF-{alpha} was provided by the MRC ADP reagent program. Human rIFN-ß was purchased from Biosource (Rungis, France). Human rTGF-ß2 was purchased from R&D Systems (Abington, U.K.). A stock solution of 3 µg/ml was prepared in 4 mM HCl containing 0.1% BSA. NG-monomethyl L-arginine (L-NMMA) and diethylamine dinitric oxide complex (DEANO) were obtained from Alexis Laboratories (COGER, Paris, France). L-tryptophan was purchased from Sigma (St. Quentin-Fallavier, France).

Protocol of infection

Confluent RPE cells were infected in eight-well glass chamber slides (Labteks, NUNC, Naperville, IL) for immunofluorescence, in 24-well plates for Western blot analysis, and in 25-cm3 culture flasks for RT-PCR analysis. High MOI (1, 2, 3, 4, 5) was used to study the effects of cytokines, whereas low MOI (0.1–0.01) was used to study the antiviral effects of organic NO donors. After a 2-h viral adsorption at 37°C in HAM-F10 without FCS, cells were washed twice with PBS and refed HAM-F10 supplemented with 10% FCS. Cytopathic effects were observed daily by light microscopy. At 5, 10, and 15 days postinfection, supernatants were collected for viral titration. Labtek slides were fixed at 2, 3, and 5 days for immunofluorescence. Proteins were extracted at the same times for Western blot analysis.

Effects of cytokines on CMV replication and viral reactivation

Confluent RPE cultures were treated the day before or simultaneously to virus adsorption with various cytokines: IFN-{gamma}, 10–100 U/ml; IFN-ß, 100–500 U/ml; TGF-ß2, 3 ng/ml; IL-1ß, 100 U/ml; TNF-{alpha}, 5–20 ng/ml or the combinations of cytokines: IFN-{gamma}, 100 U/ml + IL-1ß, 100 U/ml; IFN-{gamma}, 100 U/ml + TNF-{alpha}, 10–20 ng/ml. Controls were run in the presence of solvents used for drug or cytokine solutions. Cytokines were removed after viral adsorption in all experiments, except for IFN-{gamma} + IL-1ß used to induce and maintain the continuous production of NO. After infection, cells were harvested at different times (5, 10, and 15 days) for analysis of CMV protein expression.

To study the reversion of viral replication inhibition by IFNs, we used the classic approach of adding L-tryptophan to cells treated with either IFN-{gamma} or IFN-ß (26, 41, 42, 43). L-tryptophan (5–100 µg/ml) was added to the medium during cytokine stimulation and again at day 1 and day 2 postinfection. After a 2-h viral adsorption in the presence or absence of cytokines and/or tryptophan, cells were washed twice with PBS and refed. At 5, 10, and 15 days postinfection, supernatants were collected for virus titration and proteins were extracted for analysis of viral protein expression. The same protocol was used when L-NMMA (final concentration: 0.5 mM) was added to the cultures. L-NMMA was added simultaneously with IFN-{gamma} + IL-1ß stimulation. Nitrite levels were undetectable under these conditions (see below).

Indirect immunofluorescence assay

To follow viral protein expression, we performed indirect immunofluorescence using the following mAbs: E13 (44) (a gift from Dr. M.-C. Mazeron, Laboratoire de Virologie-Bactériologie, Hôpital Lariboisière, Paris, France) to detect immediate early (IE) proteins, F6b (45) to detect the early tegument protein pp65 (ppUL83) (46), and mAbs F4a and 87-55/02/2 (Behring, Germany, a generous gift from Dr. Walter), which detect, respectively, the late capsid protein p149 (S.M., unpublished results) and the late tegument protein pp150 (UL32) (47). Cells were seeded onto eight-well Labtek glass slides (Nunc, Naperville, IL) at 60,000 cells/well. At confluency (5 to 7 days), they were incubated with 5, 1, or 0.1 PFU of CMV per cell for 2 h, rinsed twice in PBS, and refed medium. Forty-eight hours to 5 days postinfection, depending on the MOI, cells were rinsed with PBS, air dried, and fixed in ice-cold acetone or in ethanol/acetone (V/V) for 10 min at -20°C. Cells were air dried before incubation with the first Ab. Following a 1-h incubation with the first Ab, slides were washed in PBS and incubated with a 1/80 dilution of fluorescein-conjugated anti-mouse IgG (Dako, Trappes, France). After final washing, slides were fixed with 10% formol in PBS, mounted in Vectashield, Vectalabs (Biosys SA., Compiegne, France), and examined and photographed in a Leitz Dialux microscope.

Western blot analysis

At the times indicated under Results, cells were washed twice with PBS and were lysed by addition of Lamelli’s electrophoresis buffer (0.1 ml/well of 24-well plates). Lysates were heated at 95°C for 10 min. Following SDS-PAGE electrophoresis, proteins were transferred to nylon-reinforced nitrocellulose (Sartorius, France) by semidry electrophoresis in transfer buffer (20 mM Tris-base, 150 mM glycine, 20% methanol) overnight at 30 mA. Blots were stained with 0.2% Ponceau red in 3% TCA to control the quality of transfer and saturated with 5% fat-free milk in PBS/0.1% Tween-20 (PBST) for at least 30 min at room temperature. Incubation with 5 µg/ml of primary Abs (see mAbs listed above; note that mAb E13 recognizes two proteins, IE1 and IE2) was conducted for 1 h at room temperature in saturation buffer (5% fat-free milk, PBS, 0.1% Tween-20). Following washing in PBST, blots were incubated with peroxidase-labeled anti-mouse IgG (1/400; Amersham, les Ulis, France) for 1 h at room temperature in saturation buffer. After final washing, blots were developed by chemoluminescence using ECL, according to the manufacturers’ specifications (Amersham).

Extracellular virus production

Supernatants of infected cells were sampled at the times indicated under Results and clarified of cell debris by centrifugation at 2000 rpm for 5 min in an Eppendorf centrifuge. Viral content was assessed by plaque formation under carboxymethyl cellulose, as previously described (39). Each point was run in triplicate.

Nitrite assay and treatment with exogenous NO donors

RPE cells were grown to confluency in 24-well plates and treated with IFN-{gamma} (100 U/ml) + IL-1ß (100 U/ml) to stimulate expression of NOSII (25). Cells were infected at the same time (MOI = 5) for 2 h, then washed and incubated further with the cytokines at the above concentrations. Infection with UV or heat-inactivated viruses was performed at the same MOI based on the viral titer before inactivation. At 72 h postinfection, supernatants were collected and nitrite levels were determined by a colorimetric assay based on the Griess reaction, using sodium nitrite standards. Briefly, 100 µl of cell-free supernatant was mixed with 200 µl of Griess reagent (1% sulfanilamide, 0.1% naphthyl-ethylenediamine), and, after 10 min, adsorbance was read at 540 nm. The exogenous NO donor DEANO was used at different concentrations (0.01, 0.05, 0.1, 0.25, 0.5, and 1 mM) during virus adsorption. After removal of the inoculum, cells were further incubated in the presence of DEANO and media were changed every day with freshly prepared DEANO. The t1/2 of the molecule was estimated to be 12 h. Complete inactivation of the DEANO solution was obtained after incubation in medium (pH 7.4) at room temperature for 24 h. At the end of the incubation period, cell viability was determined by trypan blue exclusion. Cells were fixed for immunofluorescence or harvested for Western blot analysis, as described above.

RNA isolation and RT-PCR-IDO mRNA expression

RPE cultures grown to confluence in 25-cm3 flasks were treated with medium alone or medium containing IFN-{gamma} (100 U/ml) or IFN-ß (500 U/ml) in the presence or absence of CMV (MOI = 5). Stimulation was stopped after 2 or 24 h. Total RNA was always prepared from cultures at 24 h using a Qiagen RNA preparation kit RNeasy (Qiagen S.A., Courteboeuf, France). Total extracted RNA was treated with RNase-free DNase and quantified spectrophotometrically. Polyadenylated mRNA was then obtained after purification with a Oligotex mRNA kit (Qiagen S.A.). Extraction and purification were performed in accordance with the manufacturers’ instructions. Polyadenylated mRNA was retrotranscribed in PCR buffer (1.5 mM MgCl2) containing 100 pmol random primers, 1 mM each deoxynucleoside triphosphate, and 200 U Superscript reverse transcriptase (Life Technologies) by incubation at 25°C for 10 min, followed by incubation at 42°C for 60 min in a final volume of 20 µl. The resulting cDNAs were amplified using 30 pmol of the primers reported by Nagineni et al. (24) for PCR amplification of IDO and 1 U of Taq polymerase. Amplification was performed with a thermocycler 9600 (Perkin-Elmer, Norwalk, CT) at 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min, for a total of 30 cycles. Samples were subjected to 1% agarose gel electrophoresis, stained with ethidium bromide, and photographed under UV light. As a positive control, human ß-actin RNA was retrotranscribed and amplified in parallel for each sample, and genomic DNA was used as a positive control for the PCR. As a negative control, an identical amount of RNA for each sample was amplified without being retrotranscribed.

Data analysis

Results are expressed as mean ± SD and were analyzed statistically by using Mann Whitney test. Statistical analysis was performed with the Statview 4.5 software package (Abacus Concepts, Berkeley, CA). Probability values of <0.05 were considered significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Influence of cytokines on CMV replication in RPE cells

Expression of viral proteins corresponding to the three phases of viral replication was analyzed by immunofluorescence and immunoblot. Two different isoforms of IE proteins (72 and 86 kDa) are the first proteins to be expressed (48). The early protein pp65 (UL83) is a matrix phosphoprotein that plays a major role in the clearance of infected cells by the immune system (49). Finally, appearance of either the late tegument protein pp150 (47) or the p149 capsid protein occurs after viral DNA synthesis and corresponds to the terminal phase of viral replication.

The initial phase of infection, monitored by immunofluorescence for IE protein expression, was not affected by any cytokine treatment, as shown in Fig. 1Go, A–C. Expression of the viral late protein pp150 was significantly inhibited after IFN-{gamma} treatment (Fig. 1Go, D and F). This treatment was ineffective when applied more than 24 h after viral adsorption (Fig. 1GoE). In contrast, treatment of cells with TNF-{alpha}, IL-1ß, or TGF-ß2 had no significant effect on CMV replication, as assessed by titration of extracellular virus production (Fig. 2Go). At 5 days postinfection (using a MOI of 5), extracellular virus production was 6.4 x 103 PFU/ml in the absence of cytokine treatment (Fig. 2Go). However, virus production was reduced significantly in the presence of IFN-{gamma} or IFN-ß, decreasing from 6.4 x 103 to 3 x 101 PFU/ml (p < 0.001) (Fig. 2Go). Cytopathic effects, observed 72 h after infection in unstimulated RPE cells, were completely abolished by IFN-{gamma} (10 U/ml) or IFN-ß (100 U/ml) treatment (data not shown). Western blot analysis confirmed these observations by showing a strong inhibition of early and late protein expression after IFN-{gamma} treatment (Fig. 3Go). The apparent inhibition of IE protein expression, as shown by Western blot analysis, was due to inhibition of the replication and propagation of progeny virus by IFN-{gamma} treatment. A pattern similar to that obtained with IFN-{gamma} was observed with IFN-ß (Fig. 3Go). These effects were dose dependent starting at 10 U/ml (IFN-{gamma}) and 50 U/ml (IFN-ß), and were maximal at 100 U/ml (IFN-{gamma}) and 500 U/ml (IFN-ß). We observed no synergistic inhibition of viral protein expression upon treatment with different cytokine combinations such as IFN-{gamma} + IL-1ß or IFN-{gamma} + TGF-ß2 (data not shown).



View larger version (53K):
[in this window]
[in a new window]
 
FIGURE 1. Effect of IFN-{gamma} treatment on CMV immediate-early and late protein expression. Human RPE cells were treated or not (NS) with IFN-{gamma} (100 U/ml) the day before (IFN-{gamma} (100 U/ml) D-1) or the day ((100 U/ml) D1) after viral adsorption (MOI: 5). A–C, IE protein expression 48 h postinfection. D–E, Late pp150 protein expression 5 days postinfection.

 


View larger version (12K):
[in this window]
[in a new window]
 
FIGURE 2. Histogram showing the influence of different cytokines on extracellular virus production by RPE cells. Cells were simultaneously treated with different cytokines (IFN-{gamma}, IFN-ß, IL-1ß, TNF-{alpha}, or TGF-ß) and infected. At 5 days postinfection, cell supernatants were collected and extracellular virus production was estimated by titration. All experiments were performed in triplicate. Means (columns) and SDs (bars) of virus titers (PFU/ml x 103) are presented. Differences in titers between IFN-{gamma}- and IFN-ß-treated cells and those treated with other cytokines or untreated cells were significant (*).

 


View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 3. Western blot analysis of CMV protein expression after IFN-{gamma} or IFN-ß treatment with or without the addition of L-tryptophan. Cells were infected in the presence of IFN-ß (100–500 U/ml) or IFN-{gamma} (10–100 U/ml) with or without different concentrations of L-tryptophan (trp20 and trp50 µg/ml). At 5 days postinfection, proteins were extracted and Western blot analysis was performed. mAb were used to detect IE (IE1 + IE2), early (pp65), and late (pp150) viral proteins.

 
IFN-induced inhibition of CMV replication is reversed by L-tryptophan

Slight cytopathic effects were seen on day 3 after infection (MOI: 5) in IFN-{gamma}-stimulated cells in the presence of 20 µg/ml of L-tryptophan. This effect was greatly enhanced in the presence of 50 µg/ml L-tryptophan and presented the same pattern as that seen in untreated, infected cells (data not shown). Increasing the concentration of L-tryptophan did not enhance its protective effect, since at high concentrations (100 µg/ml), L-tryptophan was toxic. A similar effect of tryptophan was obtained for infected cells treated with IFN-ß (data not shown). Western blot analysis of CMV protein expression confirmed the restoration of early and late viral protein synthesis upon L-tryptophan treatment, in a dose-dependent manner (Fig. 3Go). Patterns of early and late viral protein expression were similar to those in untreated, infected cells 5 days after infection (Fig. 3Go). No reversion was observed with different L-tryptophan concentrations after IFN-ß treatment at 500 U/ml. Reversion was more efficient in cells treated with IFN-{gamma} (100 U/ml) compared with those infected with IFN-ß (100 U/ml).

Extracellular virus production in cells stimulated with IFN-{gamma} or IFN-ß showed a similar profile in the presence of L-tryptophan (Fig. 4Go). CMV titers evaluated 5 days after IFN-{gamma} (100 U/ml) or IFN-ß (100 U/ml) stimulation in the presence of L-tryptophan (50 µg/ml) were, respectively, 4.3 x 103 PFU/ml and 7 x 102 PFU/ml, close to the titer observed at the same time in unstimulated infected cell supernatants (6.4 x 103 PFU/ml). To be effective, tryptophan had to be added no more than 12 h after cytokine stimulation (data not shown). In cells stimulated with a combination of IFN-{gamma} (100 U/ml) and TNF-{alpha} (20 ng/ml), the restoration profile upon L-tryptophan treatment was similar to that observed with IFN-{gamma} alone (data not shown). In all cases, reversion of IFN-{gamma} inhibition started at a minimal concentration of 5 µg/ml, progressed in a dose-dependent manner, and was maximal at 50 µg/ml. The toxic effect observed on uninfected cells at 100 µg/ml of tryptophan explains the low viral titers obtained in cells treated with 100 µg/ml of L-tryptophan (Fig. 4Go).



View larger version (15K):
[in this window]
[in a new window]
 
FIGURE 4. Virus production by RPE cells treated with IFN-{gamma} or IFN-ß at different concentrations. Cells were simultaneously infected with CMV at a high MOI (1 PFU/cell) and treated with IFN-{gamma} (100 U/ml) and IFN-ß (100 U/ml) in the absence or presence of different concentrations of L-tryptophan (trp). At 5 days postinfection, culture supernatants were collected and extracellular virus production was determined by titration. Experiments were performed in triplicate and results are expressed as mean titers (columns) and their SD (bars).

 
Complete restoration of IFN-{gamma} inhibition upon L-tryptophan treatment strongly implicated involvement of the IDO pathway induced by IFNs (26, 41, 42, 43). It has been shown previously that this pathway can be activated at the level of mRNA transcription by IFN-{gamma} and, less efficiently, by IFN-ß stimulation of RPE cells (24). To confirm these results in our RPE cells, we performed RT-PCR to detect IDO mRNA. Polyadenylated mRNA corresponding to the enzyme was detected after a 2-h stimulation with either IFN-ß or IFN-{gamma} (Fig. 5Go). The same pattern was observed when cells were stimulated for 24 h with IFN-{gamma}. However, poly(A) mRNA was no longer detectable when cells were continuously stimulated with IFN-ß for 24 h, suggesting less sustained induction compared with that by IFN-{gamma}. CMV infection had no effect on IDO transcription in unstimulated cells, nor on mRNA accumulation after IFN-{gamma} treatment.



View larger version (63K):
[in this window]
[in a new window]
 
FIGURE 5. IDO mRNA accumulation after treatment with IFNs. Cells were stimulated for 2 or 24 h with IFN-{gamma} or IFN-ß (100 U/ml). Poly(A)-mRNA was extracted and used for RT-PCR, as described in Materials and Methods. IDO mRNA was observed in uninfected (IFN{gamma}2h) and infected (IFN{gamma}2h+CMV) cells treated with IFN-{gamma}. RNA was also present in cells treated with IFN-ß for 2 h (IFNß2h). No mRNA was observed in untreated cells (NS), in CMV-infected cells (CMV), or in cells treated for 24 h with IFN-ß (IFNß24h). PC, amplification of genomic IDO DNA as a positive PCR control. As controls, human ß-actin RNA (224 bp) was retrotranscribed and amplified in parallel for each sample, and amplified genomic DNA (PC) served to control the correct size (664 bp) of IDO amplification products.

 
CMV blocks NO production in stimulated RPE cells

To evaluate the influence of endogenous NO production on viral replication, we stimulated RPE cells with a combination of IFN-{gamma} + IL-1ß, which is required to induce NOSII in these cells (25). The level of NO produced after cytokine stimulation of uninfected cells was 14.4 ± 0.8 µM. It was reduced significantly to 2.7 ± 0.3 µM after CMV infection (p < 0.001) (Fig. 6Go). This inhibition was not observed when cells were infected with UV- or heat-inactivated virus (respectively, 14.9 ± 0.5 µM and 14.6 ± 0.8 µM), suggesting a requirement for a functional CMV genome.



View larger version (12K):
[in this window]
[in a new window]
 
FIGURE 6. Nitrite production after CMV infection. Cells were stimulated with IFN-{gamma} and IL-1ß to induce the NOSII pathway and simultaneously infected with active (S+CMV), UV-inactivated (S+CMV(UV)), or heat-treated (S+CMV(heat)) virus (MOI: 5). The level of nitrite produced was evaluated by the Griess reaction. Results are expressed as µM of extracellular nitrites produced. Columns represent the means of three different experiments, each performed in triplicate. Bars indicate the SD (*, statistically significant).

 
The importance of the IDO pathway may have almost completely masked analysis of the effects of NO on CMV replication. We therefore studied the effect of an exogenously added, organic NO donor (DEANO) on viral replication. Using an MOI of 5, cytopathic effects were reduced starting at 100 µM of DEANO and were completely blocked at 250 µM (Fig. 7GoA). At this MOI, the efficiency of DEANO on cytopathic effects was comparable with that of IFN-{gamma} treatment. In terms of viral protein expression, there was a significant inhibition of early and late CMV protein expression starting at 100 µM of DEANO with a maximum at 250 µM, as assessed at 3 to 5 days postinfection by immunofluorescence (Fig. 7GoB). Cell toxicity started at 500 µM and was marked at 1 mM, which precluded testing the effect of DEANO at these concentrations. Using a low MOI (0.1), DEANO at a concentration of 50 µM strongly reduced CMV pp65 and pp150 expression at 5 days after infection (Fig. 7GoC). An inactive solution of DEANO that had previously released all available NO had no cytopathic effect on RPE cell, confirming the specific effect of NO. No toxic effect was observed on uninfected cells at the highest concentration of DEANO used, as determined by trypan blue exclusion.



View larger version (51K):
[in this window]
[in a new window]
 
FIGURE 7. Influence of exogenous NO donor on CMV-induced cytopathic effects (A), antigen expression detected by immunofluorescence (B), and late protein expression detected by imunoblot (C). A, Cells were mock infected (-) or infected (+) and treated simultaneously with DEANO, an organic NO donor. DEANO was added once per day throughout the experiments. Cytopathic effects were monitored regularly after infection by phase-contrast microscopy and were photographed 5 days after infection. B, Cells were infected at a low MOI (0.1) and treated with different concentrations of DEANO (NO µM O, 20, 50). Immunofluorescence was performed 3 days postinfection using mAb to detect an early CMV protein (anti-pp65) and a late protein (anti-pp150). C, Late viral protein expression (pp150) was monitored by Western blot analysis of proteins extracted from cells 5 days after infection at high MOI (5 PFU/cell), which were treated (NO 25 µM, NO 100 µM, NO 200 µM) or not (NS) with an NO donor (DEANO). NaOH, Treated with the solvent used for DEANO dilutions. Synthesis of a late CMV protein (pp150) was detected using a mAb.

 
The IDO pathway predominates in the inhibition of CMV replication

To determine the respective roles played by the IDO and NOSII pathways in the inhibition of CMV replication, we analyzed extracellular virus production in the presence of L-NMMA and/or L-tryptophan in cells stimulated with cytokines (IFN-{gamma}, 100 U/ml + IL-1ß, 100 U/ml), which induces the expression of both enzymes (Fig. 8Go). Levels of nitrites produced in culture supernatants after IFN-{gamma} + IL-1ß stimulation were negligible in the presence of L-NMMA (data not shown). However, extracellular virus production was still inhibited in the presence of L-NMMA, which was not surprising since CMV itself can block the NO production (reported above). Treatment of cells with IL-1ß alone had no effect on viral replication (reported above). It was clear in our model that treatment with IFN-{gamma}, or at lower efficiency with IFN-ß, sufficed to block CMV replication (reported above), therefore showing that inhibition of viral replication occurred predominantly through induction of the IDO, and not the NOSII, pathway.



View larger version (11K):
[in this window]
[in a new window]
 
FIGURE 8. Effect of adding NMMA and/or tryptophan on CMV replication in IFN-{gamma}/IL-1ß-stimulated cells. Cells were treated (S) or not (NS) with a combination of IFN-{gamma} to stimulate the IDO and IL-1ß to induce the NOSII. L-tryptophan or the NO inhibitor L-NMMA (0.5 mM) were added separately (S+Tryp50) or together (S+Tryp50 + NMMA) to cytokine-stimulated cells. Extracellular virus titers (PFU/ml x 103) were determined 5 days after infection.

 
Recovery of viral replication after cytokine removal

In cells treated with IFN-{gamma}, replication persisted at a very low level as long as IFN-{gamma} was maintained in the media (15 days). Pretreatment of cells with IFN-{gamma} or IFN-ß 1 day before infection resulted in a 5-day delay (Fig. 9Go) before detection of extracellular virus as compared with unstimulated infected cells. At 15 days after infection (end of the observation period), virus titers in supernatants of IFN-treated cells after the removal of IFN were below the level of virus production by unstimulated cells. Recovery of virus production occurred more rapidly after removal of IFN-ß than removal of IFN-{gamma}. As expected, in infected cells maintained in the presence of either type of IFN, early and late viral proteins were undetectable, although virus particles were observed by electron microscopy (data not shown).



View larger version (12K):
[in this window]
[in a new window]
 
FIGURE 9. Kinetics of CMV replication in IFN-treated cells. Extracellular virus production was evaluated by titration (PFU/ml) at 5, 10, and 15 days by untreated cells ({diamondsuit}) and cells treated with IFN-{gamma} ({blacksquare}) or IFN-ß (x) the day before infection. No extracellular virus was detected in cells continuously maintained in the presence of IFN-µ ({blacktriangleup}).

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
CMV retinitis is the major complication observed at the end stage of AIDS, accounting for 85% of CMV end-organ involvement (50). Retinal disease is closely related to the advanced level of immunosuppression. Mechanisms of retarded viral manifestations in the retina are still poorly understood. In HIV-infected patients, viral retinitis is not associated with vitreous inflammation, as is generally observed during retinitis related to herpes simplex or varicella-zoster in immunocompetent hosts (51, 52).

Previous studies have reported on the influence of different cytokines on CMV replication in vitro (53) and reviewed previously (54) and in animal models, even though results may seem contradictory to those obtained in vivo (20, 21, 55, 56, 57). In a study of a small number of patients, IFN-{gamma} and TNF-{alpha} were detected in the vitreous or the retina of HIV-infected patients at different stages of the disease (15). TGF-ß2 is constitutively present in normal eyes, actively participating in the maintenance of the ocular immune privilege. At this level, TGF-ß2 is predominantly secreted by nontransformed, cultured RPE cells (58). It can modulate expression of HLA class II Ags in IFN-{gamma}-treated RPE cells, thereby decreasing their capacity as APCs (5).

Since CMV presents strict host specificity, studies in animal models are not wholly relevant to human CMV. For this reason, we chose to study human CMV-retinal cell interactions and the effects of cytokines on CMV expression using an in vitro model based on human RPE cells. These cells are infected in vivo and have been shown to be permissive for CMV replication in vitro (10, 13). As part of the blood retinal barrier, RPE cells play an important regulatory function in infectious and inflammatory disorders.

While TNF-{alpha}, IL-1ß, and TGF-ß2 had no effect on CMV replication in RPE cells, viral protein expression and ultimately viral replication were blocked by IFN-{gamma} in a dose-dependent manner. IFN-ß was less inhibitory since the same level of inhibition required higher doses of this cytokine. CMV protein expression was shown by FACS analysis to be markedly inhibited after IFN-{gamma} treatment in a dose-dependent manner in infected fibroblasts (59). In RPE cells, we used indirect immunofluorescence to analyze viral protein expression, which is more sensitive than FACS analysis; Detrick et al. (13) previously reported very low efficiency of infection in these cells. Efficiency of viral replication was highly dependent on the MOI used.

To our knowledge, we are the first to investigate the mechanisms of IFN-induced inhibition of CMV replication. Others have shown that inhibition of T. gondii and C. psittaci replication by IFN-{gamma} involves the IDO pathway due to consumption of tryptophan (26, 27, 28), which is transformed into kynurenine and its metabolites. Nagineni et al. (24) implicated this mechanism specifically in human RPE cells infected with T. gondii. In our system, accumulation of polyadenylated IDO mRNA upon IFN-{gamma} stimulation suggested that a similar mechanism might be operable in RPE cells infected with CMV. We therefore tested whether inhibition of CMV replication could be reversed by the addition of L-tryptophan. Tryptophan reversion of IFN-{gamma} inhibition was efficient and dose dependent. RT-PCR did not show any influence of CMV infection on IDO mRNA transcription under our experimental conditions. To our knowledge, this is the first study to demonstrate that the IDO pathway induced by IFN-{gamma} is involved in the inhibition of CMV replication.

It has been shown in a model of human embryonic lung fibroblasts that CMV replication is blocked by natural human IFN-ß (53). In this model, inhibition was reportedly due to 2',5'-oligoadenylate (2–5A) synthetase, although involvement of the IDO pathway was not analyzed. It is possible that IFN-ß can induce 2',5'-oligoadenylate (2–5A) synthetase in human RPE cells, therefore explaining the incomplete and lower efficiency of reversion by L-tryptophan compared with reversion of IFN-{gamma} inhibition.

NO has antiviral effects in vitro, but can also play a substantial role in the pathogenesis of viral infections in vivo (30, 31, 32, 33, 34, 35, 60, 61). We showed previously that human RPE cells express the inducible form of NOS upon IFN-{gamma} + IL-1ß treatment, leading to production of NO (25). In this study, we addressed the question of the influence of CMV infection on NO production induced by these cytokines and, conversely, the effect of NO on CMV replication. CMV significantly down-regulated the production of NO. This was dependent on the presence of infectious virus, since no effect was observed with UV- or heat-inactivated virus. Preliminary experiments not reported herein demonstrate that NOSII mRNA accumulation after IFN-{gamma} + IL-1ß stimulation is down-regulated by CMV (O.G., unpublished results). We showed previously that CMV induces the synthesis and secretion of TGF-ß1 in fibroblasts (62). TGF-ß is known to inhibit NOSII expression, especially in RPE cells (25, 63). Thus, TGF-ß induction by CMV could be contributing to the CMV-induced inhibition of NOSII. More recently, Miller et al. (64) reported inhibition of IFN-{gamma}-induced MHC class II expression in CMV-infected endothelial cells. Induction of the transcription factor IFN-regulatory factor-1 was blocked in endothelial cells due to disruption of the JAK/STAT pathway. We have shown previously in bovine RPE cells that induction of NOSII depends on the expression of IFN-regulatory factor-1 (65). We are currently investigating whether CMV-induced inhibition of NOSII in human RPE cells also involves inhibition of IFN-regulatory factor-1.

We also studied the influence of NO on viral replication. Indeed, it has been shown, in vitro and in animal models, that NO can have significant and potent antiviral effects (30, 31, 61). To induce NO production in human RPE, cells have to be treated with IFN-{gamma}/IL-1ß (25). Treatment of cells with L-NMMA failed to increase CMV replication in IFN-{gamma}/IL-ß1-treated cells. However, due to the induction of IDO by IFN-{gamma}, we could not study the isolated effects of NO induction in this system. We therefore added organic exogenous NO donors to infected cells. There was a significant, dose-dependent block of CMV protein expression and replication, even at high MOI and in the absence of a toxic effect.

The observation that treatment of cells with L-NMMA failed to increase CMV replication in IFN-{gamma}/IL-1ß-treated cells suggests that CMV infection acts like L-NMMA in RPE cells upon induction of NO synthesis. Furthermore, the combined use of L-NMMA and L-tryptophan did not enhance viral replication above that seen with L-tryptophan alone, strongly suggesting that the inhibitory effect of the IFN-{gamma}/IL-1ß is mainly due to the induction of the IDO pathway by IFN-{gamma}. We propose a model (Fig. 10Go) of the mechanisms operating in IFN-{gamma} and/or IL-1ß-stimulated RPE cells relative to CMV replication.



View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 10. Model of the inhibition of CMV replication in IFN-{gamma} and IFN-{gamma}/IL-1ß-stimulated cells. Stimulation of RPE cells by both IFN-{gamma} and IL-1ß activates NOSII, resulting in conversion of L-arginine -> NO. CMV infection down-regulates (-) NO production induced by IFN-{gamma}/IL-1ß stimulation in infected cells. IFN-{gamma} stimulation by itself activates (+) IDO, which converts trypophan -> kynurenine, resulting in tryptophan deprivation and significantly inhibition (-) of CMV replication. Addition of L-tryptophan to IFN-{gamma}-stimulated, infected cells results in recovery of CMV replication to control levels. Thus, CMV infection can combat the synthesis of NO by NOSII, but cannot surmount activation of IDO.

 
In vivo stimulation(s) responsible for the expression of the IDO and the NOSII enzymes is unknown. Both pathways could play an antiviral role during CMV replication in vivo. We have shown that CMV down-regulation of the NOSII pathway depends on a functional viral genome. However, replication remains strongly inhibited by the IDO pathway (Fig. 9Go).

IFN-{gamma} inhibited de novo expression of the early viral protein, pp65, as shown by Western blot analysis and immunofluorescence. However, IE protein expression was not inhibited, meaning that the viral genome was effectively transported into the host cell nucleus and that cells became latently (or persistently) infected. The early viral protein pp65 is the major, immunodominant target for specific CD8+ CTLs, which confer protection from CMV disease when adoptively transferred to bone marrow transplant recipients (49, 66). Thus, CMV-infected cells in the presence of IFN-{gamma} might escape immune surveillance due to their lack of pp65 expression. Such infected cells could potentially represent sources of virus once IFN-{gamma} is no longer present. In addition, previous study showed that progressive loss of cytotoxic T cells is associated with an increased risk of CMV retinitis in HIV-infected patients (14). Finally, we show that CMV replication recovers upon removal of IFN-{gamma} and IFN-ß, indicating that functional viral genomes are conserved in cells in the presence of IFN and the absence of viral replication. Thus, cytokines such as IFN-{gamma} or IFN-ß may merely drive the virus underground before viral proteins, which are targets of the immune system, are expressed, thereby creating viral reservoirs that escape immune surveillance.


    Acknowledgments
 
We thank Dr. D. Nash for providing retinal pigment epithelial cells and Dr. Y. Courtois for helpful discussions.


    Footnotes
 
1 This work was supported by the Agence Nationale de Recherche sur le Syndrome d’Immunodéficience Acquise and by the following Biomed 2 European Concerted Action projects: Infections with HCMV in the Immunocompromised Host and ROCIO II. B.B. is a beneficiary of bursaries from the Fondation pour la Recherche Medicale, the Fondation Berthe Fouassier, and the Fonds d’Etude de l’Assistance Publique, Hôpitaux de Paris. D.Z. is a beneficiary of a Training and Mobility bursary (no. ERBFMBICT961426) from the European Commission. Back

2 Address correspondence and reprint requests to Dr. B. Bodaghi, Unité d’Immunologie Virale, 28 rue du Dr Roux, 75724 Paris, France. E-mail address: Back

3 Abbreviations used in this paper: RPE, retinal pigment epithelial; DEANO, diethylamine dinitric oxide complex; IDO, indoleamine 2,3 dioxygenase; IE, immediate early; L-NMMA, NG-monomethyl L-arginine; MOI, multiplicity of infection; NO, nitric oxide; NOSII, inducible nitric oxide synthase; PFU, plaque-forming unit. Back

Received for publication June 17, 1998. Accepted for publication October 2, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Grisanti, S., M. Ishioka, M. Kosiewicz, L. Q. Jiang, J. W. Streilein, G. A. Wilbanks, A. Taylor, S. Cousins. 1997. Immunity and immune privilege elicited by cultured retinal pigment epithelial cell transplants. Invest. Ophthalmol. Vis. Sci. 38:1619.[Abstract/Free Full Text]
  2. Wilbanks, G. A., M. Mammolenti, J. W. Streilein. 1992. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-ß. Eur. J. Immunol. 22:165.[Medline]
  3. Jiang, L. Q., M. Jorquera, J. W. Streilein. 1993. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest. Ophthalmol. Vis. Sci. 34:3347.[Abstract/Free Full Text]
  4. Griffith, T. S., T. A. Ferguson. 1997. The role of FasL-induced apoptosis in immune privilege. Immunol. Today 18:240.[Medline]
  5. Gabrielian, K., R. Osusky, B. D. Sippy, S. J. Ryan, D. R. Hinton. 1994. Effect of TGF-ß on interferon-{gamma}-induced HLA-DR expression in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 35:4253.[Abstract/Free Full Text]
  6. Ferguson, T. A., T. S. Griffith. 1997. A vision of cell death: insights into immune privilege. Immunol. Rev. 156:167.[Medline]
  7. Bok, D.. 1993. The retinal pigment epithelium: a versatile partner in vision. J. Cell Sci. 17:(Suppl.):189.
  8. Hoover, D. R., Y. Peng, A. Saah, R. Semba, R. R. Detels, C. R. Rinaldo, J. P. Phair. 1996. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch. Ophthalmol. 114:821.[Abstract/Free Full Text]
  9. Jabs, D. A., C. Enger, J. G. Bartlett. 1989. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 107:75.[Abstract/Free Full Text]
  10. Miceli, M. V., D. A. Newsome, L. C. Novak, R. W. Beuerman. 1989. Cytomegalovirus replication in cultured human retinal pigment epithelial cells. Curr. Eye Res. 8:835.[Medline]
  11. Henderly, D. E., L. R. Atalla, W. R. Freeman, N. A. Rao. 1988. Demonstration of cytomegalovirus retinitis by in situ DNA hybridization. Retina 8:177.[Medline]
  12. Burd, E. M., J. S. Pulido, D. G. Puro, W. J. O’Brien. 1996. Replication of human cytomegalovirus in human retinal glial cells. Invest. Ophthalmol. Vis. Sci. 37:1957.[Abstract/Free Full Text]
  13. Detrick, B., J. Rhame, Y. Wang, C. N. Nagineni, J. J. Hooks. 1996. Cytomegalovirus replication in human retinal pigment epithelial cells: altered expression of viral early proteins. Invest. Ophthalmol. Vis. Sci. 37:814.[Abstract/Free Full Text]
  14. Tay-kearney, M. L., C. Enger, R. D. Semba, W. Royal, J. P. Dunn, D. A. Jabs. 1997. T cell subsets and cytomegalovirus retinitis in human immunodeficiency virus-infected patients. J. Infect. Dis. 176:790.[Medline]
  15. Mondino, B. J., Y. Sidikaro, F. J. Mayer, H. L. Sumner. 1990. Inflammatory mediators in the vitreous humor of AIDS patients with retinitis. Invest. Ophthalmol. Vis. Sci. 31:798.[Abstract/Free Full Text]
  16. Hofman, F. M., D. R. Hinton. 1992. Tumor necrosis factor-{alpha} in the retina in acquired immune deficiency syndrome. Invest. Ophthalmol. Vis. Sci. 33:1829.[Abstract/Free Full Text]
  17. Boehm, U., T. Klamp, M. Groot, J. C. Howard. 1997. Cellular responses to interferon-{gamma}. Annu. Rev. Immunol. 15:749.[Medline]
  18. Castelli, J. C., B. A. Hassel, K. A. Wood, X. L. Li, K. Amemiya, M. C. Dalakas, P. F. Torrence, R. J. Youle. 1997. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5a system. J. Exp. Med. 186:967.[Abstract/Free Full Text]
  19. Haagmans, B. L., A. J. van den Eertwegh, E. Claassen, M. C. Horzinek, V. E. Schijns. 1994. Tumor necrosis factor-{alpha} production during cytomegalovirus infection in immunosuppressed rats. J. Gen. Virol. 75:779.[Abstract/Free Full Text]
  20. Lucin, P., I. Pavic, B. Polic, S. Jonjic, U. H. Koszinowski. 1992. [Gamma] interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 66:1977.[Abstract/Free Full Text]
  21. Lucin, P., S. Jonjic, M. Messerle, B. Polic, H. Hengel, U. H. Koszinowski. 1994. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-{gamma} and tumor necrosis factor. J. Gen. Virol. 75:101.[Abstract/Free Full Text]
  22. Yamamoto, N., K. Shimokata, K. Maeno, Y. Nishiyama. 1987. Effect of recombinant human interferon {gamma} against human cytomegalovirus. Arch. Virol. 94:323.[Medline]
  23. Malina, H. Z., X. D. Martin. 1993. Indoleamine 2,3-dioxygenase activity in the aqueous humor, iris/ciliary body, and retina of the bovine eye. Graefe’s Arch. Clin. Exp. Ophthalmol. 231:482.[Medline]
  24. Nagineni, C. N., K. Pardhasaradhi, M. C. Martins, B. Detrick, J. J. Hooks. 1996. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect. Immun. 64:4188.[Abstract]
  25. Goureau, O., D. Hicks, Y. Courtois. 1994. Human retinal pigmented epithelial cells produce nitric oxide in response to cytokines. Biochem. Biophys. Res. Commun. 198:120.[Medline]
  26. Taylor, M. W., G. S. Feng. 1991. Relationship between interferon-{gamma}, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5:2516.[Abstract]
  27. Pfefferkorn, E. R.. 1984. Interferon {gamma} blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. USA 81:908.[Abstract/Free Full Text]
  28. Carlin, J. M., E. C. Borden, G. I. Byrne. 1989. Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J. Interferon Res. 9:329.[Medline]
  29. Shoshkes Reiss, C., T. Komatsu. 1998. Does nitric oxide play a role in viral infections?. J. Virol. 72:4547.[Free Full Text]
  30. Lin, Y. L., Y. L. Huang, S. H. Ma, C. T. Yeh, S. Y. Chiou, L. K. Chen, C. L. Liao. 1997. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J. Virol. 71:5227.[Abstract]
  31. Karupiah, G., Q. W. Xie, R. M. Buller, C. Nathan, C. Duarte, J. D. MacMicking. 1993. Inhibition of viral replication by interferon-{gamma}-induced nitric oxide synthase. Science 261:1445.[Abstract/Free Full Text]
  32. Tucker, P. C., D. E. Griffin, S. Choi, N. Bui, S. Wesselingh. 1996. Inhibition of nitric oxide synthesis increases mortality in Sindbis virus encephalitis. J. Virol. 70:3972.[Abstract]
  33. Melkova, Z., M. Esteban. 1995. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J. Immunol. 155:5711.[Abstract]
  34. Lowenstein, C. J., S. L. Hill, A. Lafond-Walker, J. Wu, G. Allen, M. Landavere, N. R. Rose, A. Herskowitz. 1996. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest. 97:1837.[Medline]
  35. Zaragoza, C., C. J. Ocampo, M. Saura, A. McMillan, C. J. Lowenstein. 1997. Nitric oxide inhibition of coxsackievirus replication in vitro. J. Clin. Invest. 100:1760.[Medline]
  36. Becquet, F., Y. Courtois, O. Goureau. 1997. Nitric oxide in the eye: multifaceted roles and diverse outcome. Surv. Ophthalmol. 42:71.[Medline]
  37. Dighiero, P., I. Reux, J. J. Hauw, A. M. Fillet, Y. Courtois, O. Goureau. 1994. Expression of inducible nitric oxide synthase in cytomegalovirus-infected glial cells of retinas from AIDS patients. Neurosci. Lett. 166:31.[Medline]
  38. Nash, M. S., N. N. Osborne. 1995. Pertussis toxin-sensitive melatonin receptors negatively coupled to adenylate cyclase associated with cultured human and rat retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 36:95.[Abstract/Free Full Text]
  39. Alcami, J., C. V. Paya, J. L. Virelizier, S. Michelson. 1993. Antagonistic modulation of human cytomegalovirus replication by transforming growth factor ß and basic fibroblastic growth factor. J. Gen. Virol. 74:269.[Abstract/Free Full Text]
  40. Ho, W. Z., R. Cherukuri, S. D. Ge, J. R. Cutilli, L. Song, S. Whitko, S. D. Douglas. 1993. Centrifugal enhancement of human immunodeficiency virus type 1 infection and human cytomegalovirus gene expression in human primary monocytes/macrophages in vitro. J. Leukocyte Biol. 53:208.[Abstract]
  41. Beatty, W. L., T. A. Belanger, A. A. Desai, R. P. Morrison, G. I. Byrne. 1994. Tryptophan depletion as a mechanism of {gamma} interferon-mediated chlamydial persistence. Infect. Immun. 62:3705.[Abstract/Free Full Text]
  42. Brown, R. R., Y. Ozaki, S. P. Datta, E. C. Borden, P. M. Sondel, D. G. Malone. 1991. Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases and AIDS. Adv. Exp. Med. Biol. 294:425.[Medline]
  43. Takikawa, O., T. Kuroiwa, F. Yamazaki, R. Kido. 1988. Mechanism of interferon-{gamma} action: characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-{gamma} and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 263:2041.[Abstract/Free Full Text]
  44. Mazeron, M. C., G. Jahn, B. Plachter. 1992. Monoclonal antibody E-13 (M-810) to human cytomegalovirus recognizes an epitope encoded by exon 2 of the major immediate early gene. J. Gen. Virol. 73:2699.[Abstract/Free Full Text]
  45. Michelson, S., M. Tardy-Panit, O. Barzu. 1984. Properties of a human cytomegalovirus-induced protein kinase. Virology 134:259.[Medline]
  46. Amadéi, C., M. Tardy-Panit, P. Couillin, M. Coulon, N. Cabau, A. Boué, S. Michelson. 1983. Kinetic study of the development and localization of human cytomegalovirus-induced antigens using monoclonal antibodies. Ann. Virol. (Inst. Pasteur) 134E:165.
  47. Jahn, G., T. Kouzarides, M. Mach, B. C. Scholl, B. Plachter, B. Traupe, E. Preddie, S. C. Satchwell, B. Fleckenstein, B. G. Barrell. 1987. Map position and nucleotide sequence of the gene for the large structural phosphoprotein of human cytomegalovirus. J. Virol. 61:1358.[Abstract/Free Full Text]
  48. Michelson, S., F. Horodniceanu, M. Kress, M. Tardy-Panit. 1979. Human cytomegalovirus-induced immediate early antigens: analysis in sodium dodecyl sulfate-polyacrylamide gel electrophoresis after immunoprecipitation. J. Virol. 32:259.[Abstract/Free Full Text]
  49. Riddell, S. R., P. D. Greenberg. 1997. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:181.[Medline]
  50. Gallant, J. E., R. D. Moore, D. D. Richman, J. Keruly, R. E. Chaisson. 1992. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J. Infect. Dis. 166:1223.[Medline]
  51. Duker, J. S., M. S. Blumenkranz. 1991. Diagnosis and management of the acute retinal necrosis (ARN) syndrome. Surv. Ophthalmol. 35:327.[Medline]
  52. Holland, G. N.. 1994. Standard diagnostic criteria for the acute retinal necrosis syndrome: Executive Committee of the American Uveitis Society. Am. J. Ophthalmol. 117:663.[Medline]
  53. Nakamura, K., Y. Eizuru, Y. Minamishima. 1988. Effect of natural human interferon-ß on the replication of human cytomegalovirus. J. Med. Virol. 26:363.[Medline]
  54. Michelson, S.. 1998. Mechanisms of immunosuppression by human cytomegalovirus. M. Scholz, and H. F. Rabenau, and H. W. Doerr, Jrand J. Cinatl, eds. CMV-Related Immunopathology 12.-28. Karger, Basel.
  55. Haagmans, B. L., F. S. Stals, P. H. van der Meide, C. A. Bruggeman, M. C. Horzinek, V. E. Schijns. 1994. Tumor necrosis factor {alpha} promotes replication and pathogenicity of rat cytomegalovirus. J. Virol. 68:2297.[Abstract/Free Full Text]
  56. Pavic, I., B. Polic, I. Crnkovic, P. Lucin, S. Jonjic, U. H. Koszinowski. 1993. Participation of endogenous tumor necrosis factor {alpha} in host resistance to cytomegalovirus infection. J. Gen. Virol. 74:2215.[Abstract/Free Full Text]
  57. Haagmans, B. L., P. H. van der Meide, F. S. Stals, A. J. van den Eertwegh, E. Claassen, C. A. Bruggeman, M. C. Horzinek, V. E. Schijns. 1994. Suppression of rat cytomegalovirus replication by antibodies against {gamma} interferon. J. Virol. 68:2305.[Abstract/Free Full Text]
  58. Kvanta, A.. 1994. Expression and secretion of transforming growth factor-ß in transformed and nontransformed retinal pigment epithelial cells. Ophthalmic Res. 26:361.[Medline]
  59. Torigoe, S., D. E. Campbell, F. Torigoe, S. Michelson, S. E. Starr. 1993. Cytofluorographic analysis of effects of interferons on expression of human cytomegalovirus proteins. J. Virol. Methods 45:219.[Medline]
  60. Akaike, T., Y. Noguchi, S. Ijiri, K. Setoguchi, M. Suga, Y. M. Zheng, B. Dietzschold, H. Maeda. 1996. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA 93:2448.[Abstract/Free Full Text]
  61. Croen, K. D.. 1993. Evidence for antiviral effect of nitric oxide: inhibition of herpes simplex virus type 1 replication. J. Clin. Invest. 91:2446.
  62. Michelson, S., J. Alcami, S. J. Kim, D. Danielpour, F. Bachelerie, L. Picard, C. Bessia, C. Paya, J. L. Virelizier. 1994. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor ß1. J. Virol. 68:5730.[Abstract/Free Full Text]
  63. Kutty, R. K., G. Kutty, J. J. Hooks, B. Wiggert, C. N. Nagineni. 1995. Transforming growth factor-ß inhibits the cytokine-mediated expression of the inducible nitric oxide synthase mRNA in human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 215:386.[Medline]
  64. Miller, D. M., B. M. Rahill, J. M. Boss, M. D. Lairmore, J. E. Durbin, W. J. Waldman, D. D. Sedmak. 1998. Human cytomegalovirus inhibits major histocompatibility complex class Ii expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187:675.[Abstract/Free Full Text]
  65. Faure, V., Y. Courtois, O. Goureau. 1997. Inhibition of inducible nitric oxide synthase expression by interferons {alpha} and ß in bovine retinal pigmented epithelial cells. J. Biol. Chem. 272:32169.[Abstract/Free Full Text]
  66. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569.[Abstract]



This article has been cited by other articles:


Home page
J PsychopharmacolHome page
S Barry, G Clarke, P Scully, and T. Dinan
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation
J Psychopharmacol, May 1, 2009; 23(3): 287 - 294.
[Abstract] [PDF]


Home page
IOVSHome page
E. Delair, C. Creuzet, J. Dupouy-Camet, and M.-P. Roisin
In Vitro Effect of TNF-{alpha} and IFN-{gamma} in Retinal Cell Infection with Toxoplasma gondii
Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1754 - 1760.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
A. Becerra, R. V. Warke, K. Xhaja, B. Evans, J. Evans, K. Martin, N. de Bosch, A. L. Rothman, and I. Bosch
Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function
J. Gen. Virol., April 1, 2009; 90(4): 810 - 817.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
W. Yang, H. Li, P. W. Chen, H. Alizadeh, Y. He, R. N. Hogan, and J. Y. Niederkorn
PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation
Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 273 - 280.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. Mailankot, D. Smith, S. Howell, B. Wang, J. W. Jacobberger, T. Stefan, and R. H. Nagaraj
Cell Cycle Arrest by Kynurenine in Lens Epithelial Cells
Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5466 - 5475.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Baron and J.-L. Davignon
Inhibition of IFN-{gamma}-Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2
J. Immunol., October 15, 2008; 181(8): 5530 - 5536.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Wang, Q.-C. Yu, J. Schroer, E. Murphy, and T. Shenk
Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells
PNAS, December 11, 2007; 104(50): 20037 - 20042.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. C. Cuffy, A. M. Silverio, L. Qin, Y. Wang, R. Eid, G. Brandacher, F. G. Lakkis, D. Fuchs, J. S. Pober, and G. Tellides
Induction of Indoleamine 2,3-Dioxygenase in Vascular Smooth Muscle Cells by Interferon-{gamma} Contributes to Medial Immunoprivilege
J. Immunol., October 15, 2007; 179(8): 5246 - 5254.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
H.-S. Suh, M.-L. Zhao, M. Rivieccio, S. Choi, E. Connolly, Y. Zhao, O. Takikawa, C. F. Brosnan, and S. C. Lee
Astrocyte Indoleamine 2,3-Dioxygenase Is Induced by the TLR3 Ligand Poly(I:C): Mechanism of Induction and Role in Antiviral Response
J. Virol., September 15, 2007; 81(18): 9838 - 9850.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. P. Moraes, T. de los Santos, M. Koster, T. Turecek, H. Wang, V. G. Andreyev, and M. J. Grubman
Enhanced Antiviral Activity against Foot-and-Mouth Disease Virus by a Combination of Type I and II Porcine Interferons
J. Virol., July 1, 2007; 81(13): 7124 - 7135.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. Zhang, J. Zhou, B. Marshall, H. Xin, and S. S. Atherton
Lack of iNOS Facilitates MCMV Spread in the Retina
Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
R. L. Seymour, V. Ganapathy, A. L. Mellor, and D. H. Munn
A high-affinity, tryptophan-selective amino acid transport system in human macrophages
J. Leukoc. Biol., December 1, 2006; 80(6): 1320 - 1327.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Agaugue, L. Perrin-Cocon, F. Coutant, P. Andre, and V. Lotteau
1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity
J. Immunol., August 15, 2006; 177(4): 2061 - 2071.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. E. Dobbs, J. E. Strasser, C.-F. Chu, C. Chalk, and G. N. Milligan
Clearance of Herpes Simplex Virus Type 2 by CD8+ T Cells Requires Gamma Interferon and either Perforin- or Fas-Mediated Cytolytic Mechanisms
J. Virol., December 1, 2005; 79(23): 14546 - 14554.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
K. Obojes, O. Andres, K. S. Kim, W. Daubener, and J. Schneider-Schaulies
Indoleamine 2,3-Dioxygenase Mediates Cell Type-Specific Anti-Measles Virus Activity of Gamma Interferon
J. Virol., June 15, 2005; 79(12): 7768 - 7776.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
F. Halary, V. Pitard, D. Dlubek, R. Krzysiek, H. de la Salle, P. Merville, C. Dromer, D. Emilie, J.-F. Moreau, and J. Dechanet-Merville
Shared reactivity of V{delta}2neg {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells
J. Exp. Med., May 16, 2005; 201(10): 1567 - 1578.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Terness, J.-J. Chuang, T. Bauer, L. Jiga, and G. Opelz
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?
Blood, March 15, 2005; 105(6): 2480 - 2486.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
J. E. Eickhoff and M. Cotten
NF-{kappa}B activation can mediate inhibition of human cytomegalovirus replication
J. Gen. Virol., February 1, 2005; 86(2): 285 - 295.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. H. Munn, M. D. Sharma, and A. L. Mellor
Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells
J. Immunol., April 1, 2004; 172(7): 4100 - 4110.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
O. Adams, K. Besken, C. Oberdorfer, C. R. MacKenzie, O. Takikawa, and W. Daubener
Role of Indoleamine-2,3-Dioxygenase in Alpha/Beta and Gamma Interferon-Mediated Antiviral Effects against Herpes Simplex Virus Infections
J. Virol., March 1, 2004; 78(5): 2632 - 2636.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. L. Mellor, B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn
Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion
J. Immunol., August 15, 2003; 171(4): 1652 - 1655.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. L. Mellor and D. H. Munn
Tryptophan Catabolism and Regulation of Adaptive Immunity
J. Immunol., June 15, 2003; 170(12): 5809 - 5813.
[Full Text] [PDF]


Home page
Am. J. Pathol.Home page
I. Kosugi, H. Kawasaki, Y. Arai, and Y. Tsutsui
Innate Immune Responses to Cytomegalovirus Infection in the Developing Mouse Brain and Their Evasion by Virus-Infected Neurons
Am. J. Pathol., September 1, 2002; 161(3): 919 - 928.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
P. Terness, T. M. Bauer, L. Rose, C. Dufter, A. Watzlik, H. Simon, and G. Opelz
Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase-expressing Dendritic Cells: Mediation of Suppression by Tryptophan Metabolites
J. Exp. Med., August 19, 2002; 196(4): 447 - 457.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-H. Chiou, J.-H. Liu, W.-M. Hsu, S. S.-L. Chen, S.-Y. Chang, L.-J. Juan, J.-C. Lin, Y.-T. Yang, W.-W. Wong, C.-Y. Liu, et al.
Up-Regulation of Fas Ligand Expression by Human Cytomegalovirus Immediate-Early Gene Product 2: A Novel Mechanism in Cytomegalovirus-Induced Apoptosis in Human Retina
J. Immunol., October 1, 2001; 167(7): 4098 - 4103.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
B. Ebrahimi, B. M. Dutia, D. G. Brownstein, and A. A. Nash
Murine Gammaherpesvirus-68 Infection Causes Multi-Organ Fibrosis and Alters Leukocyte Trafficking in Interferon-{{gamma}} Receptor Knockout Mice
Am. J. Pathol., June 1, 2001; 158(6): 2117 - 2125.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Noda, K. Tanaka, S.-a. Sawamura, M. Sasaki, T. Matsumoto, K. Mikami, Y. Aiba, H. Hasegawa, N. Kawabe, and Y. Koga
Role of Nitric Oxide Synthase Type 2 in Acute Infection with Murine Cytomegalovirus
J. Immunol., March 1, 2001; 166(5): 3533 - 3541.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
R. M. Presti, D. L. Popkin, M. Connick, S. Paetzold, and H. W. Virgin IV
Novel Cell Type-Specific Antiviral Mechanism of Interferon {gamma} Action in Macrophages
J. Exp. Med., February 19, 2001; 193(4): 483 - 496.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
B. Detrick, C. N. Nagineni, L. R. Grillone, K. P. Anderson, S. P. Henry, and J. J. Hooks
Inhibition of Human Cytomegalovirus Replication in a Human Retinal Epithelial Cell Model by Antisense Oligonucleotides
Invest. Ophthalmol. Vis. Sci., January 1, 2001; 42(1): 163 - 169.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
M. C.-J. Cheeran, S. Hu, G. Gekker, and J. R. Lokensgard
Decreased Cytomegalovirus Expression Following Proinflammatory Cytokine Treatment of Primary Human Astrocytes
J. Immunol., January 15, 2000; 164(2): 926 - 933.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. F. Pais and R. Appelberg
Macrophage Control of Mycobacterial Growth Induced by Picolinic Acid Is Dependent on Host Cell Apoptosis
J. Immunol., January 1, 2000; 164(1): 389 - 397.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bodaghi, B.
Right arrow Articles by Michelson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bodaghi, B.
Right arrow Articles by Michelson, S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS